Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours
A Phase Ib, Dose Finding Study Evaluating AZD1775 in Monotherapy, in Combination With Carboplatin and Paclitaxel, and in Combination With Only Carboplatin in Adult Asian Patients With Advanced Solid Tumours
Sponsor: AstraZeneca
A PHASE1 clinical study on Advanced Solid Tumours, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 12 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE1
▶ Show 7 earlier versions
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Jun 2018 — Apr 2019 [monthly]
Completed PHASE1
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jun 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE1
Status: Enrolling By Invitation → Active Not Recruiting
-
Mar 2017 — Jun 2017 [monthly]
Enrolling By Invitation PHASE1
Status: Active Not Recruiting → Enrolling By Invitation
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Jan 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .